Professor Thomas Scriba

SATVI

Affiliations

  1. Full Member, Institute of Infectious Disease and Molecular Medicine

  2. Deputy Director (Immunology), South African Tuberculosis Vaccine Initiative (SATVI) 

Key Expertise

Biomarker Discovery, Omics, Pathogenesis, T-and B-cell Immunology, TB, Vaccine Design, Vaccine Development

Main Research Focus

Tom Scriba interests focus on understanding the immunopathology of Mycobacterium tuberculosis infection and TB disease developing correlates of risk and immunological correlates of protection against TB. He also focuses on TB vaccine development.

Most Significant Paper Authored in 2025

BCG Revaccination for the Prevention of Mycobacterium tuberculosis Infection

Schmidt AC, Fairlie L, Hellström E, Luabeya Kany Kany A, Middelkoop K, Naidoo K, Nair G, Gela A, Nemes E, Scriba TJ, Cinar A, Frahm N, Mogg R, Kaufman D, Dunne MW, Hatherill M, BCG REVAX Study Team (2025) 

This paper reports the results of a phase 2b vaccine trial that assessed the efficacy of BCG revaccination in prevention of Mycobacterium tuberculosis infection in adolescents.